Adam A Kraya1, Kara N Maxwell2, Monika A Eiva3, Bradley Wubbenhorst1, John Pluta1, Michael Feldman3, Anupma Nayak3, Daniel J Powell3, Susan M Domchek2,4, Robert H Vonderheide2,4, Katherine L Nathanson2,4. 1. Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. 2. Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. 3. Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. 4. Basser Center for BRCA and Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Abstract
PURPOSE: Ovarian cancers can exhibit a prominent immune infiltrate, but clinical trials have not demonstrated substantive response rates to immune checkpoint blockade monotherapy. We aimed to understand genomic features associated with immunogenicity in BRCA1/2 mutation-associated cancers. MATERIALS AND METHODS: Using the Cancer Genome Atlas whole-exome sequencing, methylation, and expression data, we analyzed 66 ovarian cancers with either germline or somatic loss of BRCA1/2 and whole-exome sequencing, immunohistochemistry, and CyTOF in 20 ovarian cancers with germline BRCA1/2 pathogenic variants from Penn. RESULTS: We found two groups of BRCA1/2 ovarian cancers differing in their immunogenicity: (1) 37 tumors significantly enriched for PTEN loss (11, 30%) and BRCA1 promoter-hypermethylated (10, 27%; P = .0016) and (2) PTEN wild-type (28 of 29 tumors) cancers, with the latter group having longer overall survival (OS; P = .0186, median OS not reached v median OS = 66.1 months). BRCA1/2-mutant PTEN loss and BRCA1 promoter-hypermethylated cancers were characterized by the decreased composition of lymphocytes estimated by gene expression (P = .0030), cytolytic index (P = .034), and cytokine expression but higher homologous recombination deficiency scores (P = .00013). Large-scale state transitions were the primary discriminating feature (P = .001); neither mutational burden nor neoantigen burden could explain differences in immunogenicity. In Penn tumors, PTEN loss and high homologous recombination deficiency cancers exhibited fewer CD3+ (P = .05), CD8+ (P = .012), and FOXP3+ (P = .0087) T cells; decreased PRF1 expression (P = .041); and lower immune costimulatory and inhibitory molecule expression. CONCLUSION: Our study suggests that within ovarian cancers with genetic loss of BRCA1/2 are two subsets exhibiting differential immunogenicity, with lower levels associated with PTEN loss and BRCA hypermethylation. These genomic features of BRCA1/2-associated ovarian cancers may inform considerations around how to optimally deploy immune checkpoint inhibitors in the clinic.
PURPOSE: Ovarian cancers can exhibit a prominent immune infiltrate, but clinical trials have not demonstrated substantive response rates to immune checkpoint blockade monotherapy. We aimed to understand genomic features associated with immunogenicity in BRCA1/2 mutation-associated cancers. MATERIALS AND METHODS: Using the Cancer Genome Atlas whole-exome sequencing, methylation, and expression data, we analyzed 66 ovarian cancers with either germline or somatic loss of BRCA1/2 and whole-exome sequencing, immunohistochemistry, and CyTOF in 20 ovarian cancers with germline BRCA1/2 pathogenic variants from Penn. RESULTS: We found two groups of BRCA1/2 ovarian cancers differing in their immunogenicity: (1) 37 tumors significantly enriched for PTEN loss (11, 30%) and BRCA1 promoter-hypermethylated (10, 27%; P = .0016) and (2) PTEN wild-type (28 of 29 tumors) cancers, with the latter group having longer overall survival (OS; P = .0186, median OS not reached v median OS = 66.1 months). BRCA1/2-mutant PTEN loss and BRCA1 promoter-hypermethylated cancers were characterized by the decreased composition of lymphocytes estimated by gene expression (P = .0030), cytolytic index (P = .034), and cytokine expression but higher homologous recombination deficiency scores (P = .00013). Large-scale state transitions were the primary discriminating feature (P = .001); neither mutational burden nor neoantigen burden could explain differences in immunogenicity. In Penn tumors, PTEN loss and high homologous recombination deficiency cancers exhibited fewer CD3+ (P = .05), CD8+ (P = .012), and FOXP3+ (P = .0087) T cells; decreased PRF1 expression (P = .041); and lower immune costimulatory and inhibitory molecule expression. CONCLUSION: Our study suggests that within ovarian cancers with genetic loss of BRCA1/2 are two subsets exhibiting differential immunogenicity, with lower levels associated with PTEN loss and BRCA hypermethylation. These genomic features of BRCA1/2-associated ovarian cancers may inform considerations around how to optimally deploy immune checkpoint inhibitors in the clinic.
Authors: U A Matulonis; R Shapira-Frommer; A D Santin; A S Lisyanskaya; S Pignata; I Vergote; F Raspagliesi; G S Sonke; M Birrer; D M Provencher; J Sehouli; N Colombo; A González-Martín; A Oaknin; P B Ottevanger; V Rudaitis; K Katchar; H Wu; S Keefe; J Ruman; J A Ledermann Journal: Ann Oncol Date: 2019-07-01 Impact factor: 32.976
Authors: Robert A Soslow; Guangming Han; Kay J Park; Karuna Garg; Narciso Olvera; David R Spriggs; Noah D Kauff; Douglas A Levine Journal: Mod Pathol Date: 2011-12-23 Impact factor: 7.842
Authors: F Favero; T Joshi; A M Marquard; N J Birkbak; M Krzystanek; Q Li; Z Szallasi; A C Eklund Journal: Ann Oncol Date: 2014-10-15 Impact factor: 32.976
Authors: Kyle C Strickland; Brooke E Howitt; Sachet A Shukla; Scott Rodig; Lauren L Ritterhouse; Joyce F Liu; Judy E Garber; Dipanjan Chowdhury; Catherine J Wu; Alan D D'Andrea; Ursula A Matulonis; Panagiotis A Konstantinopoulos Journal: Oncotarget Date: 2016-03-22
Authors: W Y Mansour; P Tennstedt; J Volquardsen; C Oing; M Kluth; C Hube-Magg; K Borgmann; R Simon; C Petersen; E Dikomey; K Rothkamm Journal: Sci Rep Date: 2018-03-02 Impact factor: 4.379
Authors: Filipe Correia Martins; Dominique-Laurent Couturier; Anna Paterson; Anthony N Karnezis; Christine Chow; Tayyebeh M Nazeran; Adekunle Odunsi; Aleksandra Gentry-Maharaj; Aleksandra Vrvilo; Alexander Hein; Aline Talhouk; Ana Osorio; Andreas D Hartkopf; Angela Brooks-Wilson; Anna DeFazio; Anna Fischer; Arndt Hartmann; Brenda Y Hernandez; Bryan M McCauley; Chloe Karpinskyj; Christiani B de Sousa; Claus Høgdall; Daniel G Tiezzi; Esther Herpel; Florin Andrei Taran; Francesmary Modugno; Gary Keeney; Gregg Nelson; Helen Steed; Honglin Song; Hugh Luk; Javier Benitez; Jennifer Alsop; Jennifer M Koziak; Jenny Lester; Joseph H Rothstein; Jurandyr M de Andrade; Lene Lundvall; Luis Paz-Ares; Luis Robles-Díaz; Lynne R Wilkens; Maria J Garcia; Maria P Intermaggio; Marie-Lyne Alcaraz; Mary A Brett; Matthias W Beckmann; Mercedes Jimenez-Linan; Michael Anglesio; Michael E Carney; Michael Schneider; Nadia Traficante; Nadja Pejovic; Naveena Singh; Nhu Le; Peter Sinn; Prafull Ghatage; Ramona Erber; Robert Edwards; Robert Vierkant; Roberta B Ness; Samuel Leung; Sandra Orsulic; Sara Y Brucker; Scott H Kaufmann; Sian Fereday; Simon Gayther; Stacey J Winham; Stefan Kommoss; Tanja Pejovic; Teri A Longacre; Valerie McGuire; Valerie Rhenius; Weiva Sieh; Yurii B Shvetsov; Alice S Whittemore; Annette Staebler; Beth Y Karlan; Cristina Rodriguez-Antona; David D Bowtell; Ellen L Goode; Estrid Høgdall; Francisco J Candido Dos Reis; Jacek Gronwald; Jenny Chang-Claude; Kirsten B Moysich; Linda E Kelemen; Linda S Cook; Marc T Goodman; Peter A Fasching; Robin Crawford; Suha Deen; Usha Menon; David G Huntsman; Martin Köbel; Susan J Ramus; Paul D P Pharoah; James D Brenton Journal: Br J Cancer Date: 2020-06-18 Impact factor: 7.640